首页/数据集/Additional file 2: of SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials

Additional file 2: of SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials

Figshare2017-12-16 更新2026-04-08 收录

糖尿病临床试验

核心结局集

数据链接：

https://springernature.figshare.com/articles/Additional_file_2_of_SCORE-IT_Selecting_Core_Outcomes_for_Randomised_Effectiveness_trials_In_Type_2_diabetes_a_systematic_review_of_registered_trials/5709331/1 数据链接链接失效反馈

官方服务：

资源简介：

List of all included studies. (XLSX 10 kb)

应用场景：

创建时间：

2017-12-16

糖尿病临床试验

慢性肾病药物疗效

Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes melli

NIAID Data Ecosystem40

Dataset from A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

糖尿病临床试验

复方制剂疗效评估

Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week

NIAID Data Ecosystem10

Available IPD datapackage for study 'A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus'

糖尿病临床试验

剂量反应关系

To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes

DataCite Commons2024-12-02 更新00

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Treatment With SYR-472 in Subjects With Type 2 Diabetes

糖尿病临床试验

2型糖尿病药物疗效

The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise,

DataCite Commons2024-12-02 更新30

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy

糖尿病临床试验

长期疗效评估

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in co

DataCite Commons2025-12-08 更新10

Additional file 2: of SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials

资源简介：

相关数据集